Bioventus Inc.
BVS
$9.15
-$0.36-3.79%
| 12/31/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.45% | 15.04% | 10.32% | 8.73% | 7.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.45% | 15.04% | 10.32% | 8.73% | 7.62% |
| Cost of Revenue | 3.79% | 8.27% | -0.77% | -9.00% | -4.89% |
| Gross Profit | 18.95% | 18.64% | 16.29% | 19.56% | 16.33% |
| SG&A Expenses | 10.43% | 16.07% | 9.94% | -3.03% | 1.19% |
| Depreciation & Amortization | -15.89% | -10.88% | -10.03% | -17.57% | 36.23% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.29% | 13.01% | 5.78% | -6.11% | -2.73% |
| Operating Income | 330.66% | 79.50% | 78.22% | 143.79% | 124.03% |
| Income Before Tax | 102.76% | 41.01% | -806.92% | 94.93% | 74.09% |
| Income Tax Expenses | 173.33% | -1.83% | -2,026.25% | 721.23% | 93.16% |
| Earnings from Continuing Operations | 95.85% | 38.33% | -578.76% | 94.02% | 64.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 100.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -89.62% | -59.88% | 673.33% | -93.06% | -81.07% |
| Net Income | 97.44% | 33.94% | -551.78% | 96.72% | 80.91% |
| EBIT | 330.66% | 79.50% | 78.22% | 143.79% | 124.03% |
| EBITDA | 71.18% | 7.92% | 22.46% | 379.00% | -25.27% |
| EPS Basic | 97.52% | 36.40% | -536.90% | 96.78% | 81.26% |
| Normalized Basic EPS | 177.53% | 72.06% | 2,240.96% | -124.44% | 84.12% |
| EPS Diluted | 97.52% | 36.40% | -536.90% | 96.78% | 81.26% |
| Normalized Diluted EPS | 177.53% | 72.06% | 2,240.96% | -124.44% | 84.12% |
| Average Basic Shares Outstanding | 3.73% | 3.87% | 2.41% | 2.02% | 1.89% |
| Average Diluted Shares Outstanding | 3.73% | 3.87% | 2.41% | 2.02% | 1.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
